<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2020-13-3-88-91</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-492</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FOR OPHTHALMOLOGY PRACTITIONERS</subject></subj-group></article-categories><title-group><article-title>Редкий случай глазных осложнений лечения стромальной опухоли желудка иматиниба мезилатом</article-title><trans-title-group xml:lang="en"><trans-title>A rare case of eye complications of gastric stromal tumor treatment using imatinib mesylate</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мякошина</surname><given-names>Е. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Myakoshina</surname><given-names>E. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Борисовна Мякошина — кандидат медицинских наук, научный сотрудник отдела офтальмоонкологии и радиологии.</p><p>Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Elena B. Myakoshina — Cand. of Med.  Sci.,  researcher, department of ophthalmooncology and radiology.</p><p>105062, 14/19, Sadovaya-Chernogryazskaya st., Moscow</p></bio><email xlink:type="simple">myakoshina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саакян</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Saakyan</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Ваговна Саакян — доктор медицинских наук, профессор, руководитель отдела офтальмоонкологии и радиологии.</p><p>Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Svetlana V. Saakyan — Dr. of Med. Sci., Professor, head of the department of ophthalmooncology and radiology.</p><p>105062, 14/19, Sadovaya-Chernogryazskaya st., Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>15</day><month>09</month><year>2020</year></pub-date><volume>13</volume><issue>3</issue><fpage>88</fpage><lpage>91</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мякошина Е.Б., Саакян С.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Мякошина Е.Б., Саакян С.В.</copyright-holder><copyright-holder xml:lang="en">Myakoshina E.B., Saakyan S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/492">https://roj.igb.ru/jour/article/view/492</self-uri><abstract><p>Цель работы — описать  клинический случай  глазных  осложнений  лечения  стромальной  опухоли  желудка  иматиниба мезилатом.</p><sec><title>Материал  и методы</title><p>Материал  и методы.  Пациентка 78 лет обследована  с помощью общеофтальмологических и инструментальных методов, включая ультразвуковое исследование  и спектральную оптическую когерентную томографию (СОКТ).</p></sec><sec><title>Результаты</title><p>Результаты. С помощью офтальмоскопии диагностированы стушеванность макулярного рефлекса правого глаза. В левом глазу также  выявлена нечеткость границ диска зрительного нерва (ДЗН) и макулярного рефлекса,  наличие в парамакулярной зоне белесоватых фокусов серо-желтого цвета, неправильной формы, с ровными четкими границами, в нижнем отделе глазного дна — слабопигментированного серо-желтого фокуса с неровными нечеткими границами, неровной поверхностью. CОКТ показала в правом глазу в макуле и парамакулярных зонах ретинальный отек, эпиретинальную мембрану. По краям ДЗН левого глаза — витреоретинальные тракции, отек сетчатки; в парамакулярной зоне и во внутренних отделах глазного дна — витреоретинальные тракции, эпиретинальный  фиброз, ретинальный  отек; в нижних отделах — полная деструкция всех слоев сетчатки из-за гиперрефлективного фокуса с мелкобугристым внутренним контуром, ровный хориоидальный профиль с истончением хориоидеи, витреоретинальные тракции, эпиретинальная мембрана.</p></sec><sec><title>Заключение</title><p>Заключение. Клинический случай глазных осложнений применения  иматиниба мезилата  в лечении стромальной опухоли желудка свидетельствует о необходимости междисциплинарного комплексного подхода (онколога и офтальмоонколога) к диагностике и лечению  опухолевых  заболеваний. Комплекс  инструментальных методов диагностики заболеваний глазного дна с включением дополнительных уточняющих методов (СОКТ) дает возможность провести дифференциальную диагностику ретинопатии на фоне химиотерапии, вторичного метастатического поражения и витреоретинальной патологии  другого этиопатогенеза. Ранняя диагностика позволяет  провести адекватное лечение для сохранения  зрения, глаза и жизни больного.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose: to describe a clinical case of ocular complications of gastric stromal tumor treatment with imatinib mesylate.</p></sec><sec><title>Material  and methods</title><p>Material  and methods. A patient aged 78 was examined  by general ophthalmologic and instrumental  methods,  including ultrasound  and spectral optical coherence tomography (SOCT).</p></sec><sec><title>Results</title><p>Results. Ophthalmoscopy  helped diagnose a blunted foveal reflex of the right eye. In the left eye, fuzzy boundaries of the optic disc edema and the macular reflex, the presence of gray-yellow foci of an irregular shape with even distinct boundaries in the paramacular zone were revealed. In the lower part of the left eye fundus, a weakly pigmented gray-yellow focus with uneven indistinct boundaries and an uneven  surface was to be seen. SOCT showed in the right eye a retinal edema in the macula  and paramacular  zones and an epiretinal membrane.  In the left eye, SOCT showed vitreoretinal tractions and retinal edema on the edges of the optic nerve; in the paramacular  zone and in the inner parts of the fundus,  vitreoretinal tractions, epiretinal fibrosis, retinal edema was observed whilst in the lower parts of the fundus complete destruction of all retinal layers due to the hyperreflective focus with a small-shaped inner contour, an even choroidal profile with thinning of the choroid, vitreoretinal tractions, and epiretinal membrane  in the left eye could be seen.</p></sec><sec><title>Conclusions</title><p>Conclusions. The clinical case of eye complications of imatinib mesylate in the treatment of gastric stromal tumor necessitates an interdisciplinary integrated approach (involving an oncologist and an ocular oncologist) in the diagnosis and treatment of eye tumors. A complex of instrumental methods of diagnostics of eye fundus diseases involving additional refinement methods (SOCT) ensures differential diagnosis of retinopathy during the chemotherapy, secondary metastatic involvement, and vitreoretinal pathology of a different pathogenetic etiology. Early diagnosis facilitates providing adequate treatment aimed at preserving the patient’s vision, the eye, and life.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>иматиниба мезилат</kwd><kwd>глазные осложнения</kwd><kwd>спектральная оптическая когерентная томография</kwd></kwd-group><kwd-group xml:lang="en"><kwd>imatinib mesylate</kwd><kwd>eye complications</kwd><kwd>spectral optical  coherence tomography</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Roskoski R. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacological Res. 2015; 100: 1–23. doi:http://dx.doi.org/10.1016/j.phrs.2015.07.010</mixed-citation><mixed-citation xml:lang="en">Roskoski  R. A historical overview  of protein kinases  and  their  targeted small molecule inhibitors. Pharmacological Res. 2015; 100: 1–23. doi:http://dx.doi.org/10.1016/j.phrs.2015.07.010</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Savage D.G., Antman K.H. Imatinib mesylate – a new oral targeted therapy. N. Engl. J. Med. 2002; 346: 683–93. doi: 10.1056/NEJMra013339</mixed-citation><mixed-citation xml:lang="en">Savage D.G.,  Antman  K.H.  Imatinib mesylate  – a new oral targeted therapy. N. Engl. J. Med.  2002; 346: 683–93. doi: 10.1056/NEJMra013339</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ami E.B., Demetri G.D. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. Expert Opinion on Drug Safety. 2016; 15 (4): 571–8.</mixed-citation><mixed-citation xml:lang="en">Ami E.B., Demetri G.D. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. Expert Opinion on Drug Safety. 2016; 15 (4): 571–8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009; 6 (8): 465–77. doi: 10.1038/nrclinonc.2009.94</mixed-citation><mixed-citation xml:lang="en">Chen  H.X.,  Cleck  J.N.  Adverse  effects  of anticancer agents  that  target  the VEGF pathway. Nat.  Rev.  Clin.  Oncol. 2009;  6 (8):  465–77. doi:  10.1038/nrclinonc.2009.94</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Shimazaki C., Ochiai N., Uchida R., et al. Intramuscular edema as a complication of treatment with imatinib. Leukemia. 2003; 17: 804–5. doi:10.1038/sj.leu.2402868</mixed-citation><mixed-citation xml:lang="en">Shimazaki C., Ochiai N., Uchida R., et al. Intramuscular edema as a complication of treatment with  imatinib. Leukemia. 2003;  17: 804–5. doi:10.1038/sj.leu.2402868</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ebnoether M., Stentoft J., Ford J., Buhl L., Gratwohl A. Cerebral oedema as a possible complication of treatment with imatinib. Lancet. 2002; 359: 1751–2. doi: 10.1016/S0140-6736(02)08616-6</mixed-citation><mixed-citation xml:lang="en">Ebnoether M., Stentoft J., Ford J., Buhl L.,  Gratwohl A. Cerebral oedema as a possible complication of treatment with imatinib. Lancet. 2002; 359: 1751–2. doi: 10.1016/S0140-6736(02)08616-6</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kusumi E., Arakawa A., Kami M., et al. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia. 2004; 18: 1138–9. doi: 10.1038/sj.leu.2403364</mixed-citation><mixed-citation xml:lang="en">Kusumi E., Arakawa A., Kami M., et al. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia. 2004;  18: 1138–9. doi:  10.1038/sj.leu.2403364</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fraunfelder F.W., Solomon J., Druker B.J., Esmaeli B., Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J. Ocul. Pharmacol. Ther. 2003; 19: 371–5. doi: 10.1089/108076803322279426</mixed-citation><mixed-citation xml:lang="en">Fraunfelder F.W., Solomon J., Druker B.J., Esmaeli B., Kuyl J. Ocular side-effects associated with imatinib mesylate  (Gleevec). J. Ocul. Pharmacol. Ther.  2003; 19: 371–5. doi: 10.1089/108076803322279426</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Crystal D., Shenouda-Awad N., Haskes C., Wrzesinski S. Imatinib Mesylate (Gleevec) induced unilateral optic disc edema. Optometry and Vision Science. Oct 2012; 89 (10): 16–22. doi: 10.1097/OPX.0b013e318269111d</mixed-citation><mixed-citation xml:lang="en">Crystal D., Shenouda-Awad N.,  Haskes  C.,  Wrzesinski S. Imatinib Mesylate (Gleevec) induced unilateral optic disc edema. Optometry and Vision Science. Oct 2012; 89 (10): 16–22. doi: 10.1097/OPX.0b013e318269111d</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Pietras K., Ostman A., Sjoquist M., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001; 61: 2929–34. PMID: 11306470</mixed-citation><mixed-citation xml:lang="en">Pietras K., Ostman A., Sjoquist M., et al. Inhibition of platelet-derived growth factor  receptors reduces interstitial hypertension and  increases transcapillary transport in tumors. Cancer Res. 2001; 61: 2929–34. PMID: 11306470</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997; 277: 242–5. doi: 10.1126/science.277.5323.242</mixed-citation><mixed-citation xml:lang="en">Lindahl P.,  Johansson  B.R.,  Leveen  P.,  Betsholtz  C.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.  Science. 1997;  277: 242–5. doi: 10.1126/science.277.5323.242</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Koleske A.J., Gifford A.M., Scott M.L., et al. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron. 1998 Dec; 21 (6): 1259–72. doi: 10.1016/s0896-6273(00)80646-7</mixed-citation><mixed-citation xml:lang="en">Koleske  A.J.,  Gifford A.M.,  Scott M.L., et al. Essential roles  for the  Abl and Arg tyrosine  kinases in neurulation. Neuron. 1998 Dec;  21 (6): 1259–72. doi: 10.1016/s0896-6273(00)80646-7</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Robbins S.G., Mixon R.N., Wilson D.J., et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest. Ophthalmol. Vis. Sci. 1994 Sep; 35: 3649–63. PMID:8088954</mixed-citation><mixed-citation xml:lang="en">Robbins S.G.,  Mixon  R.N., Wilson  D.J.,  et al. Platelet-derived growth  factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest. Ophthalmol. Vis. Sci. 1994 Sep; 35: 3649–63. PMID:8088954</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Саакян С.В., Мякошина Е.Б., Юровская Н.Н., Рябина М.В. Метастатическая карцинома хориоидеи: два клинических случая. Вестник офтальмологии. 2013; 2: 58–62.</mixed-citation><mixed-citation xml:lang="en">Saakyan S.V., Myakoshina E.B., Yurovskaya N.N., Ryabina  M.V.  Choroidal metastatic carcinoma: two clinical  cases.Vestnik oftal'mologii. 2013; 2: 58–62 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Нероев В.В. Современные аспекты лечения диабетического макулярного отека. Российский офтальмологический журнал. 2012; 5 (1): 4–7.</mixed-citation><mixed-citation xml:lang="en">Neroev  V.V.  Modern aspects  of the  treatment of diabetic macular edema. Russian ophthalmological journal. 2012; 5 (1): 4–7 (in Russian).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
